Bambusa Therapeutics, Inc.
Bambusa Therapeutics, Inc. filed Amendment No. 1 to Form S-1 for an initial public offering of 9,375,000 common shares at an expected price of $15.00 to $17.00 per share. Underwriters have a 30-day option to purchase up to 1,406,250 additional shares. Lead candidate BBT001 reported positive July 2026 topline proof-of-concept data in moderate-to-severe atopic dermatitis, with Week 6 placebo-adjusted EASI-75 of 64%.
- Offering covers 9,375,000 common shares at an expected $15.00 to $17.00 per share.
- Company applied to list on Nasdaq Global Select Market under the symbol BBTX.
- BBT001 topline PoC update included all 17 enrolled moderate-to-severe AD patients.
- Week 6 placebo-adjusted EASI-50 was 82%.
- Week 6 placebo-adjusted EASI-75 was 64%.
Price data unavailable.
A bispecific antibody developer with early positive atopic dermatitis efficacy data is seeking a Nasdaq IPO, offering exposure to a projected $200 billion immunology market.
The offering positions Bambusa within a global immunology and inflammation market the prospectus projects to exceed $200 billion by 2030.
The BBT001 proof-of-concept dataset is based on only 17 evaluable patients as of June 8, 2026. Nasdaq listing is a closing condition, and there has been no prior public market for the common stock.